Papers

2

Total Citations

38

H-Index

2

About

Weizhong He is a leading researcher in urological oncology and surgical robotics, with a focus on improving functional outcomes after radical prostatectomy. His most cited work, a 2014 Phase 4 multicenter randomized controlled trial, demonstrated that solifenacin succinate significantly accelerates the return to urinary continence following robotic-assisted radical prostatectomy—a landmark study cited 33 times that directly addresses a critical quality-of-life issue for prostate cancer survivors. This work established He as a key investigator in post-surgical bladder dysfunction management. More recently, He has pioneered innovative approaches to surgical precision, authoring a 2023 proof-of-concept study on neural signals-based respiratory motion tracking. This cutting-edge research aims to eliminate system latency in thoracoabdominal radiotherapy and robotic surgery, potentially revolutionizing real-time motion compensation. By integrating neurophysiological signals with surgical robotics, He is bridging the gap between neural control and automated surgical assistance. His contributions span from high-impact clinical trials to translational engineering, reflecting a rare dual expertise in evidence-based medicine and biomedical device innovation.

Research Focus

Key Achievements

2
H-Index
2
Papers
38
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy
33 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: Astellas Pharma (United States), Electrical Geodesics (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago